Sign in
Taking people in United StatesNo phase

Follows pregnant people with migraine who take rimegepant

Tracks outcomes for mothers, fetuses and infants after rimegepant exposure.

Key facts

Who runs it
Pfizer
Where
Wilmington, United StatesSee the site
Trial code
Registry title
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
Status
Recruiting
People taking part
780 people, planned
Started
23 Sept 2021
Expected to end
30 Apr 2034
Type of study
Observational, 2 groups
Treatments tested
  • Rimegepant
  • Not taking Rimegepant
Record updated
29 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for pregnant women with migraine. One group took rimegepant during or just before pregnancy. The other group did not take it.

Age
The record gives a minimum age of 0 years and no upper limit.
Sex
Women only.
Disease stage
A diagnosis of migraine, during pregnancy.
Earlier treatment
Exposed group: at least 1 dose of rimegepant during pregnancy or up to 3 days before conception. Comparison group: no rimegepant before or during pregnancy.

Main reasons for not taking part

  • Women who took other CGRP antagonists (for example ubrogepant) during pregnancy or just before it
  • Women who took CGRP monoclonal antibodies during pregnancy or just before it
  • Women who took ditans (for example lasmiditan) during pregnancy or just before it

This trial only enrols pregnant participants. The registry sentence this rests on: Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)

The registry criteria, word for word

Show all 3 criteriaShow less

Who can take part

  • Pregnant women with migraine exposed to rimegepant: a diagnosis of migraine and at least 1 dose of rimegepant during pregnancy or just prior to pregnancy (up to 3 days prior to conception)
  • Pregnant women with migraine unexposed to rimegepant: a diagnosis of migraine and no exposure to Rimegepant before or during pregnancy

Who cannot take part

  • Women exposed to other calcitonin gene-related peptide (CGRP)antagonists (e.g., ubrogepant), CGRP monoclonal antibodies, or ditans (e.g., lasmiditan) at any time during pregnancy or just prior to pregnancy

Where in United States

  • Evidera, a PPD business unitWilmington, United StatesTaking people

About the trial

What the trial wants to find out

The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.

The 2 groups in the trial

  • Pregnant women with migraine exposed to Rimegepant

    Pregnant women with a diagnosis of migraine who are exposed to rimegepant at any time during pregnancy or just prior to pregnancy (up to 3 days prior to conception)

    Treatment: Rimegepant

  • Pregnant women with migraine not exposed to Rimegepant

    Pregnant women with a diagnosis of migraine who are not exposed to rimegepant (up to 5 product half-lives prior to conception) but who may be exposed to other products for the treatment/prevention of migraine at any time during pregnancy or just prior to pregnancy

    Treatment: Not taking Rimegepant

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Prospective, Registry-based, Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant: The Migraine Observational Nurtec Pregnancy Registry (MONITOR)
Plain-language title
Follows pregnant people with migraine who take rimegepantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
29 October 2026